On March 15, CDC escalated the 2024 measles outbreak program-led response to a center-led response to efficiently coordinate resources in support of existing and emerging requests from multiple jurisdictions. CDC is monitoring, and responding as appropriate, to potential public health threats, posed by several outbreaks of measles. HPP and PHEP Recipients who have questions regarding the response, should contact their CDC health department liaison officers and/or ASPR Field Project Officers.
Additionally, per CDC’s recommendation, the U.S. Department of Transportation’s Pipeline and Hazardous Materials Safety Administration issued a safety advisory notice on March 11 regarding diagnostic samples and clinical waste containing Monkeypox virus (MPXV) in Clade I and II. The recommendation clarifies that samples and clinical waste should be designated as Category B infectious substances except when they contain or are contaminated with cultures of Clade I MPXV.
PHMSA, in partnership with the CDC, will continue to monitor the current Mpox outbreak—as well as any future outbreaks.